cisplatin resistant lung adenocarcinoma cell line a549 ddp  (Procell Inc)

Journal: Communications Biology

Article Title: Dual targeting of topoisomerase I and DNA G-quadruplexes enhances senescence and chemosensitivity in colorectal cancer

doi: 10.1038/s42003-026-09801-w

Figure Lengend Snippet: A , B Inhibition of cell viability in HCT116-DDP and HCT8-5FU resistant cells treated with ZBH-01, CPT-11, SN-38, 5-FU, and DDP, or combination of ZBH-01 (10 nM) with 5-FU and ZBH-01 (1 μM) with DDP (MTT assay). Data represent mean ± SEM from at least three independent experiments. IC 50 values were determined using IBM SPSS Statistics (Version 26). C Combination index (CI) and Relative inhibition (RI) analysis in HCT116-DDP cells treated with ZBH-01 and DDP at the indicated concentrations for 72 h. CI < 1 indicates synergy; CI < 0.3 indicates strong synergy; CI > 1 indicates antagonism. D , E RT-qPCR analysis of gene expression in HCT116-DDP cells after treatment for 24 h with DMSO, ZBH-01 (2 µM), SN-38 (2 µM), CPT-11 (2 µM), DDP (25 µM) or the combinations of ZBH-01 + DDP. Data are presented as mean ± S.D. ( n ≥ 3 independent experiments per condition). p -values for each comparison were determined using a two-tailed unpaired Student’s t -test.

Article Snippet: The HCT116-DDP cell line was cultured in RPMI-1640 (Sigma-Aldrich) supplemented with 10% FBS (Biological Industries), 1% Pen Strep (Gibco), and 1 μg/ml cisplatin (MCE, HY-17394) to maintain resistance.

Techniques: Inhibition, MTT Assay, Quantitative RT-PCR, Gene Expression, Comparison, Two Tailed Test

Journal: The Journal of Biological Chemistry

Article Title: Photodynamic activation of a KRAS RNA G-quadruplex–targeted photosensitizer induces ferroptosis in cisplatin-resistant non–small cell lung cancer

doi: 10.1016/j.jbc.2026.111181

Figure Lengend Snippet: Binding of MC1 to KRAS RG4 in tumor cells. A, Live A549/DDP cells stained with MC1 (2 μM), MitoTracker Red and DAPI. B, Live A549/DDP cells stained with MC1 (2 μM), with or without the pretreatment of DMS. C , Fixed A549/DDP cells stained MC1 (2 μM), with or without the pretreatment of DNase I or RNase A. D, Relative ratio of Renilla luciferase activity to Firefly luciferase activity in psiCHECK-2 vector containing mutant or wild-type 5′-UTR of KRAS, without or with the presence of MC1 . The data represent the mean ± SD (n = 5), ∗∗∗ for p < 0.001, ∗∗∗∗ for p < 0.0001 compared to the control group. RG4, RNA G-quadruplex; FL, Firefly luciferase; RL, Renilla luciferase.

Article Snippet: The authenticity of A549/DDP cell line (Procell) was validated using STR profiling, and the cell line was tested free from mycoplasma contamination.

Techniques: Binding Assay, Staining, Luciferase, Activity Assay, Plasmid Preparation, Mutagenesis, Control

Journal: The Journal of Biological Chemistry

Article Title: Photodynamic activation of a KRAS RNA G-quadruplex–targeted photosensitizer induces ferroptosis in cisplatin-resistant non–small cell lung cancer

doi: 10.1016/j.jbc.2026.111181

Figure Lengend Snippet: Antiproliferation effects of MC1 in tumor cells. A and B, transcription and expression of RAS-related genes in A549/DDP cells after 24-h treatment ( MC1 for 1 h, irradiation with 495 nm, 12.5 mW/cm 2 for 15 min, and culture for another 24 h), examined by RT-PCR and Western blot. C , ROS levels of A549/DDP cells after 24-h treatment, examined by DCFH-DA. D and E, apoptosis of A549/DDP cells after 24-h treatment, examined by Annexin V-PI staining and Western blot. F, growth inhibition of A549/DDP cells after 7-days treatment, examined by MCTS and PI staining. The data represent the mean ± SD (n = 3), ∗∗ for p < 0.01, ∗∗∗∗ for p < 0.0001 compared to the control group.

Article Snippet: The authenticity of A549/DDP cell line (Procell) was validated using STR profiling, and the cell line was tested free from mycoplasma contamination.

Techniques: Expressing, Irradiation, Reverse Transcription Polymerase Chain Reaction, Western Blot, Staining, Inhibition, Control

Journal: The Journal of Biological Chemistry

Article Title: Photodynamic activation of a KRAS RNA G-quadruplex–targeted photosensitizer induces ferroptosis in cisplatin-resistant non–small cell lung cancer

doi: 10.1016/j.jbc.2026.111181

Figure Lengend Snippet: Ferroptosis and ICD effects of MC1 in tumor cells. A and B, GSH and NADH levels of A549/DDP cells after 24-h treatment ( MC1 for 1 h, irradiation with 495 nm, 12.5 mW/cm 2 for 15 min, and culture for another 24 h). C and D, LPO levels of A549/DDP cells after 24-h treatment, examined by flow cytometry and confocal microscopy. E, typical proteins of ferroptosis and ICD in A549/DDP cells after 24-h treatment, examined by Western blot. F, CRT expression on the surface of A549/DDP cells after 24-h treatment, examined by flow cytometry. G, extracellular ATP levels of A549/DDP cells after 24-h treatment. The data represent the mean ± SD (n = 3), ∗∗ for p < 0.01, ∗∗∗ for p < 0.001, ∗∗∗∗ for p < 0.0001 compared to the control group. ICD, immunogenic cell death; LPO, lipid peroxide; CRT, calreticulin; GSH-GPX4, glutathione peroxidase 4; HMGB1, high mobility group box 1.

Article Snippet: The authenticity of A549/DDP cell line (Procell) was validated using STR profiling, and the cell line was tested free from mycoplasma contamination.

Techniques: Irradiation, Flow Cytometry, Confocal Microscopy, Western Blot, Expressing, Control

Journal: The Journal of Biological Chemistry

Article Title: Photodynamic activation of a KRAS RNA G-quadruplex–targeted photosensitizer induces ferroptosis in cisplatin-resistant non–small cell lung cancer

doi: 10.1016/j.jbc.2026.111181

Figure Lengend Snippet: Imaging and antiproliferation effects of MC1 in vivo . A, fluorescence images of A549/DDP-bearing mice with intratumoral injection of MC1 (100 μM, 100 μl) for 0 h and 24 h, as well as the major organs and tumors of the mice harvested for 24 h. B, images of the excised tumors from A549/DDP-bearing mice treated with control, and MC1-Light (100 μM, 100 μl MC1 injection as well as irradiation with 495 nm, 12.5 mW/cm 2 for 30 min) every other day for 24 days. C , tumor growth curves displaying the tumor volumes measured every other day until 24 days after tumor implantation. D, tumor weights determined at the time of sacrifice. The data represent the mean ± SD (n = 4), ∗∗ for p < 0.01, ∗∗∗∗ for p < 0.0001 compared to the control group.

Article Snippet: The authenticity of A549/DDP cell line (Procell) was validated using STR profiling, and the cell line was tested free from mycoplasma contamination.

Techniques: Imaging, In Vivo, Fluorescence, Injection, Control, Irradiation, Tumor Implantation

Journal: Translational Cancer Research

Article Title: m6A modified circPTK2 mediates TNBC chemotherapy resistance

doi: 10.21037/tcr-2025-1-2634

Figure Lengend Snippet: The expression and localization of circPTK2 in TNBC cells. (A) Sanger sequencing confirmed the circular structure of circPTK2; (B) qRT-PCR detected the expression of circPTK2 in the parental and drug-resistant cells of TNBC; (C) different concentrations of DDP treatment of the drug-resistant cells MDA-MB-231/DDP, qRT-PCR detected the expression of circPTK2; (D) qRT-PCR detected the expression of circPTK2 after RNase R digestion in the drug-resistant cells; (E) qRT-PCR detected the stability of circPTK2 after actinomycin treatment; (F) RNA FISH verified the localization of circPTK2 in MDA-MB-231/DDP cells. Original magnification: ×200. *, P<0.05; **, P<0.01. circRNA, circular RNA; DDP: cisplatin; qRT-PCR, quantitative reverse transcription polymerase chain reaction; RNA FISH, RNA fluorescence in situ hybridization; TNBC, triple-negative breast cancer.

Article Snippet: DDP (Cisplatin Injection, Qilu Pharmaceutical, Jinan, China; generic name: cisplatin) was dosed uniformly at 75 mg/m 2 per cycle for all patients.

Techniques: Expressing, Sequencing, Quantitative RT-PCR, Reverse Transcription, Polymerase Chain Reaction, Fluorescence, In Situ Hybridization

Journal: Translational Cancer Research

Article Title: m6A modified circPTK2 mediates TNBC chemotherapy resistance

doi: 10.21037/tcr-2025-1-2634

Figure Lengend Snippet: The expression of circPTK2 in the tissues and plasma of TNBC sensitive and resistant patients. (A) qRT-PCR was used to detect the expression levels of circPTK2 in DDP-sensitive and DDP-resistant tissues; (B) Kaplan-Meier survival curve was used to evaluate the relationship between the expression of circPTK2 and patient prognosis; (C) ROC curve was used to assess the sensitivity and specificity of detecting the expression of circPTK2 in tissues; (D) qRT-PCR was used to detect the expression level of circPTK2 in the plasma of DDP-sensitive and DDP-resistant patients; (E) ROC curve was used to evaluate the sensitivity and specificity of detecting the plasma circPTK2. circRNA, circular RNA; DDP, cisplatin; qRT-PCR, quantitative reverse transcription polymerase chain reaction; ROC, receiver operating characteristic; TNBC, triple-negative breast cancer.

Article Snippet: DDP (Cisplatin Injection, Qilu Pharmaceutical, Jinan, China; generic name: cisplatin) was dosed uniformly at 75 mg/m 2 per cycle for all patients.

Techniques: Expressing, Clinical Proteomics, Quantitative RT-PCR, Reverse Transcription, Polymerase Chain Reaction

Journal: Translational Cancer Research

Article Title: m6A modified circPTK2 mediates TNBC chemotherapy resistance

doi: 10.21037/tcr-2025-1-2634

Figure Lengend Snippet: The role of circPTK2 in the sensitivity of TNBC cells to DDP. (A) qRT-PCR was used to detect the knockdown efficiency of circPTK2 siRNA fragments. After the expression of circPTK2 was knocked down in MDA-MB-231/DDP and MDA-MB-468/DDP cells, (B,C) cell viability was detected by CCK-8 method; (D,E) cell invasion ability was detected by Transwell method, Transwell assays were stained with crystal violet; original magnification: ×200; (F,G) the number of γH2AX focus positive cells was detected after treatment with 5 µM DDP for 0, 4, and 8 h. Original magnification: ×400. (H) The number of γH2AX foci in cells after 4 h of DDP treatment were detected by immunofluorescence staining. (I) The protein expression levels of caspase-3, cleaved-caspase-3, γH2AX and BRCA1 were detected by W-B experiment. *, P<0.05; **, P<0.01. CCK-8, Cell Counting Kit-8; circRNA, circular RNA; DDP, cisplatin; qRT-PCR, quantitative reverse transcription polymerase chain reaction; W-B, Western Blot.

Article Snippet: DDP (Cisplatin Injection, Qilu Pharmaceutical, Jinan, China; generic name: cisplatin) was dosed uniformly at 75 mg/m 2 per cycle for all patients.

Techniques: Quantitative RT-PCR, Knockdown, Expressing, CCK-8 Assay, Staining, Immunofluorescence, Cell Counting, Reverse Transcription, Polymerase Chain Reaction, Western Blot

Journal: Translational Cancer Research

Article Title: m6A modified circPTK2 mediates TNBC chemotherapy resistance

doi: 10.21037/tcr-2025-1-2634

Figure Lengend Snippet: circPTK2 binds to miR-495 through its ceRNA activity. (A) RIP-PCR experiment to detect whether circPTK2 can bind to AGO2 protein; (B) database prediction of miRNAs interacting with circPTK2; (C) expression of pull-down candidate miRNAs after overexpression of circPTK2 in MDA-MB-231/DDP cells; (D) detection of miR-495 expression in MDA-MB-231/DDP cells after co-transfection of si-circPTK2 and anti-miR-495 by qRT-PCR; (E) binding site of circPTK2 and miR-495; (F) FISH co-localization of circPTK2 and miR-495. Original magnification: ×400. **, P<0.01. DDP, cisplatin; FISH, fluorescence in situ hybridization; qRT-PCR, quantitative reverse transcription polymerase chain reaction; RIP-PCR, RNA immunoprecipitation followed by polymerase chain reaction.

Article Snippet: DDP (Cisplatin Injection, Qilu Pharmaceutical, Jinan, China; generic name: cisplatin) was dosed uniformly at 75 mg/m 2 per cycle for all patients.

Techniques: Activity Assay, Expressing, Over Expression, Cotransfection, Quantitative RT-PCR, Binding Assay, Fluorescence, In Situ Hybridization, Reverse Transcription, Polymerase Chain Reaction, RNA Immunoprecipitation

Journal: Translational Cancer Research

Article Title: m6A modified circPTK2 mediates TNBC chemotherapy resistance

doi: 10.21037/tcr-2025-1-2634

Figure Lengend Snippet: The targeted binding of miR-495 to β-catenin. (A) The sequencing results of the entire transcriptome mRNA. (B) Bioinformatics prediction of downstream target genes of miR-495. (C) The mutated sequence of the 3'UTR of β-catenin. (D) Dual luciferase reporter gene assay to detect cell activity. (E) qRT-PCR to detect the expression level of β-catenin in DDP-sensitive and DDP-resistant patient tissues. (F) qRT-PCR and W-B (G) detection of the mRNA and protein expression levels of β-catenin in the parental TNBC and DDP-resistant cells. *, P<0.05; **, P<0.01. 3'UTR, 3' untranslated region; DDP, cisplatin; mRNA, messenger RNA; qRT-PCR, quantitative reverse transcription polymerase chain reaction; TNBC, triple-negative breast cancer; W-B, Western Blot.

Article Snippet: DDP (Cisplatin Injection, Qilu Pharmaceutical, Jinan, China; generic name: cisplatin) was dosed uniformly at 75 mg/m 2 per cycle for all patients.

Techniques: Binding Assay, Sequencing, Luciferase, Reporter Gene Assay, Activity Assay, Quantitative RT-PCR, Expressing, Reverse Transcription, Polymerase Chain Reaction, Western Blot

Journal: Translational Cancer Research

Article Title: m6A modified circPTK2 mediates TNBC chemotherapy resistance

doi: 10.21037/tcr-2025-1-2634

Figure Lengend Snippet: Schematic diagram of the hypothesis that m 6 A modification mediates circPTK2 regulation of TNBC DDP resistance. DDP, cisplatin; m 6 A, N6-methyladenosine; TNBC, triple-negative breast cancer.

Article Snippet: DDP (Cisplatin Injection, Qilu Pharmaceutical, Jinan, China; generic name: cisplatin) was dosed uniformly at 75 mg/m 2 per cycle for all patients.

Techniques: Modification